- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03619980
A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the Disease Trajectories Until Progression or Death
Retrospective Study to Evaluate Time to Event and Healthcare Resource Utilization of Prostate Cancer Patients Throughout the Disease Stages, From m0HSPC, m1HSPC, m0CRPC, m1CRPC Until Progression or Death
Primary objective of this study is to describe the time in each prostate cancer stage from non-metastatic Hormone Sensitive Prostate Cancer (m0HSPC), metastatic Hormone Sensitive Prostate Cancer (m1HSPC), non-metastatic Castrate-Resistant Prostate Cancer (m0CRPC), metastatic Castrate-Resistant Prostate Cancer (m1CRPC) to progression or death.
The secondary objectives of this study are to describe co-medication at each disease stage, to describe co-morbidities at each disease stage and to describe the healthcare resource use and costs associated to each disease stage.
Study Overview
Detailed Description
This is a retrospective analysis of Prostate Cancer patients from m0HSPC, m1HSPC, m0CRPC, m1CRPC followed in the Prostate Cancer Database Sweden (PCBaSe) database. The patient population consists of men recorded in Patient-overview Prostate Cancer (PPC) between 1 January 2014 until death or 31 December 2016. Patient history to 2006 was collected by retrospective charted review.
Data will be extracted from PPC for the different Prostate Cancer (PCa) disease stages, from m0HSPC, m1HSPC, m0CRPC, m1CRPC until progression or death. The prostate cancer disease progression from m0HSPC, m1HSPC, m0CRPC, m1CRPC until progression or death has not been recorded in a systematic way. Given the complexity of this disease, the aim of this study is to have a comprehensive understanding about the disease progression in prostate cancer, from m0HSPC, m1HSPC, m0CRPC, m1CRPC until progression or death.
In addition, the following will be collected: co-morbidities, co-medication, health care resource utilization and costs, as well as other health economic variables such as sick leave and early retirement at the different disease stages.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden, 753 09
- Site SE46001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients registered in PPC.
Exclusion Criteria:
- None.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Participants with prostate cancer
This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
|
Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time from entry to exit either by progression or death from prostate cancer stage m0HSPC
Time Frame: 11 years
|
M0HSPC as defined by date for start of ADT (Androgen Deprivation Therapy) (bicalutamide or hormone therapy) and no date for metastatic disease.
|
11 years
|
Measure: Time from entry to exit either by progression or death from prostate cancer stage m1HSPC
Time Frame: 11 years
|
M1HSPC as defined by date for start of ADT (bicalutamide or hormone therapy) and date for metastatic disease.
|
11 years
|
Time from entry to exit either by progression or death from prostate cancer stage m0CRPC
Time Frame: 11 years
|
M0CRPC as defined by date for clinical assessment of CRPC (Castration Resistant Prostate Cancer) or PSA (Prostate-Specific Antigen) progression ((while on GnRH (Gonadotropin-Releasing Hormone) analogues)) and no date for metastases.
|
11 years
|
Time from entry to exit either by progression or death from prostate cancer stage m1CRPC
Time Frame: 11 years
|
m1CRPC as defined by date for clinical assessment of CRPC or PSA progression (while on GnRH analogues) and confirmed by date for radiographic progression or initiation of treatment for mCRPC (metastatic castration-resistant prostate cancer).
|
11 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Co-morbidities at disease stage m0HSPC
Time Frame: 11 years
|
The prevalence of different co-morbidities of interest will be summarized for each disease stage.
|
11 years
|
Co-morbidities at disease stage m1HSPC
Time Frame: 11 years
|
The prevalence of different co-morbidities of interest will be summarized for each disease stage.
|
11 years
|
Co-morbidities at disease stage m0CRPC
Time Frame: 11 years
|
The prevalence of different co-morbidities of interest will be summarized for each disease stage.
|
11 years
|
Co-morbidities at disease stage m1CRPC
Time Frame: 11 years
|
The prevalence of different co-morbidities of interest will be summarized for each disease stage.
|
11 years
|
Co-medications at disease stage m0HSPC as recorded in the registries
Time Frame: 11 years
|
The prevalence of different co-medications of interest will be summarized for each disease stage.
|
11 years
|
Co-medications at disease stage m1HSPC as recorded in the registries
Time Frame: 11 years
|
The prevalence of different co-medications of interest will be summarized for each disease stage.
|
11 years
|
Co-medications at disease stage m0CRPC as recorded in the registries
Time Frame: 11 years
|
The prevalence of different co-medications of interest will be summarized for each disease stage.
|
11 years
|
Co-medications at disease stage m1CRPC as recorded in the registries
Time Frame: 11 years
|
The prevalence of different co-medications of interest will be summarized for each disease stage.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by number of prostate cancer treatment regimens
Time Frame: 11 years
|
Healthcare resource utilization and related costs for each disease stage will be assessed by number of prostate cancer treatment regimens.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by number of prostate cancer treatment regimens
Time Frame: 11 years
|
Healthcare resource utilization and related costs for each disease stage will be assessed by number of prostate cancer treatment regimens.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by number of prostate cancer treatment regimens
Time Frame: 11 years
|
Healthcare resource utilization and related costs for each disease stage will be assessed by number of prostate cancer treatment regimens.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by number of prostate cancer treatment regimens
Time Frame: 11 years
|
Healthcare resource utilization and related costs for each disease stage will be assessed by number of prostate cancer treatment regimens.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by type of prostate cancer treatment regimens
Time Frame: 11 years
|
Healthcare resource utilization and related costs for each disease stage will be assessed by type of prostate cancer treatment regimens.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by type of prostate cancer treatment regimens
Time Frame: 11 years
|
Healthcare resource utilization and related costs for each disease stage will be assessed by type of prostate cancer treatment regimens.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by type of prostate cancer treatment regimens
Time Frame: 11 years
|
Healthcare resource utilization and related costs for each disease stage will be assessed by type of prostate cancer treatment regimens.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by type of prostate cancer treatment regimens
Time Frame: 11 years
|
Healthcare resource utilization and related costs for each disease stage will be assessed by type of prostate cancer treatment regimens.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by hospitalization in-patient
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization in-patient.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by hospitalization in-patient
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization in-patient.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by hospitalization in-patient
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization in-patient.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by hospitalization in-patient
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization in-patient.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by hospitalization frequency
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization frequency.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by hospitalization frequency
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization frequency.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by hospitalization frequency
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization frequency.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by hospitalization frequency
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization frequency.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by hospitalization duration
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization duration.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by hospitalization duration
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization duration.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by hospitalization duration
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization duration.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by hospitalization duration
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by hospitalization duration.
Disease coding is according to International Classification of Diseases 10th Edition (ICD-10).
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by type of hospital visits
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of hospital visits.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by type of hospital visits
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of hospital visits.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by type of hospital visits
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of hospital visits.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by type of hospital visits
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of hospital visits.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by frequency of hospital visits
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of hospital visits.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by frequency of hospital visits
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of hospital visits.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by frequency of hospital visits
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of hospital visits.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by frequency of hospital visits
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of hospital visits.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by type of imaging examinations
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of imaging examinations.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by type of imaging examinations
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of imaging examinations.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by type of imaging examinations
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of imaging examinations.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by type of imaging examinations
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of imaging examinations.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by frequency of imaging examinations
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of imaging examinations.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by frequency of imaging examinations
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of imaging examinations.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by frequency of imaging examinations
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of imaging examinations.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by frequency of imaging examinations
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of imaging examinations.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by type of laboratory tests
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of laboratory tests.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by type of laboratory tests
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of laboratory tests.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by type of laboratory tests
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of laboratory tests.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by type of laboratory tests
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by type of laboratory tests.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0HSPC as measured by frequency of laboratory tests
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of laboratory tests
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1HSPC as measured by frequency of laboratory tests
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of laboratory tests.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m0CRPC as measured by frequency of laboratory tests
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of laboratory tests.
|
11 years
|
Healthcare resource utilization and related costs in disease stage m1CRPC as measured by frequency of laboratory tests
Time Frame: 11 years
|
Healthcare resource utilization and related costs will be assessed by frequency of laboratory tests.
|
11 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Astellas Pharma Europe Ltd., Astellas Pharma Europe Ltd.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9785-MA-3167
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on No intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
Wright State UniversityCompleted